Introduction to Animal Models of Sleep Disorders/Insomnia

Sleep‑disorder/insomnia animal models are commonly used in neuropsychiatric research to mimic human disturbances in sleep architecture and abnormalities in the wake–sleep rhythm. These models are typically established through environmental manipulations—such as sleep deprivation or alterations in light–dark cycles—pharmacological induction—for example, with caffeine—or genetic engineering. Such models can elicit phenotypes including prolonged sleep latency, reduced total sleep duration, and disrupted non‑rapid eye movement (NREM) and rapid eye movement (REM) sleep patterns, often accompanied by imbalances in neurotransmitters like GABA, 5‑HT, and DA, as well as dysregulation of hypothalamic arousal‑promoting systems. Consequently, they are widely employed for screening sedative–hypnotic agents and investigating the mechanisms underlying sleep regulation.

Service Advantages of the Aniphe Biolaboratory Animal Model Platform for Sleep Disorders/Insomnia

Aniphe Biolaboratory sleep disorder/insomnia animal model platform, centered on standardized modeling through multiple induction methods and the capability to stably reconstruct sleep rhythms, provides a reliable in vivo evaluation system for the development of sedative–hypnotic drugs and for research into the mechanisms of sleep regulation.

	Multi‑type modeling approaches have been refined. It encompasses mainstream insomnia models, including sleep deprivation, light‑cycle manipulation, and pharmacological induction, and is adaptable to various research settings.
	Standardization of Rhythm Intervention Light/dark cycles, deprivation duration, and stimulus intensity are strictly controlled according to standard operating procedures to minimize experimental variability.
	Sleep phenotypes are stable and reliable. It can stably induce a typical phenotype characterized by prolonged sleep latency, reduced total sleep duration, and disrupted sleep architecture.
	Multi‑time‑window evaluation support It covers the acute induction phase, the recovery phase, and the drug‑free washout period, making it suitable for dynamic study designs.
	The multi-dimensional evaluation system has been refined. Systematic assessment is achieved through the integration of behavioral monitoring, EEG/EMG recordings, and biochemical marker analysis.

Modeling cycle	1–6 weeks
Laboratory animals	Primarily using adult SD rats and C57BL/6 mice.
Positive drug	Sedative–hypnotic agents: diazepam (a benzodiazepine, GABA-A receptor agonist), zolpidem (a non‑benzodiazepine), and melatonin (a melatonin receptor agonist, used in circadian rhythm disorder models); wakefulness‑promoting agents for validating sleepiness models: modafinil. In some studies, eszopiclone or ramelteon was used as a positive control.
Application areas	Pharmacological screening of novel sedative–hypnotic agents (such as orexin receptor antagonists) and wake-promoting drugs; mechanistic studies on the cognitive and metabolic impairments associated with insomnia; investigations into the links between circadian rhythm disruption and neurodegenerative disorders (e.g., Alzheimer’s disease); and exploration of the regulatory mechanisms underlying the locus coeruleus–noradrenergic and orexin/hypocretin pathways.

Construction of Animal Models of Sleep Disorders/Insomnia

01 Platform-based sleep deprivation method: A small platform is placed in the aquatic environment; during sleep, animals experience reduced muscle tone, which disrupts their sleep and induces continuous or intermittent sleep deprivation, enabling the study of the effects of sleep loss.

02 Light‑dark rhythm disruption method: By prolonging light exposure, reversing the day–night cycle, or employing irregular light–dark cycles, this approach disrupts circadian regulation, leading to dysregulation of the sleep–wake rhythm and mimicking a state of chronic insomnia.

03 Chemical Induction Method: By administering stimulants such as caffeine or compounds that modulate neurotransmitters, this approach disrupts sleep-regulatory pathways, leading to phenotypes such as difficulty falling asleep and reduced sleep duration.